Public Employees Retirement Association of Colorado Cuts Stake in Zoetis Inc. (NYSE:ZTS)

Public Employees Retirement Association of Colorado reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,186,703 shares of the company's stock after selling 26,699 shares during the quarter. Zoetis makes up approximately 0.8% of Public Employees Retirement Association of Colorado's investment portfolio, making the stock its 25th largest position. Public Employees Retirement Association of Colorado owned approximately 0.26% of Zoetis worth $193,350,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Mission Wealth Management LP raised its holdings in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after acquiring an additional 59 shares in the last quarter. VeraBank N.A. raised its holdings in shares of Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after acquiring an additional 62 shares in the last quarter. HUB Investment Partners LLC raised its holdings in shares of Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after acquiring an additional 62 shares in the last quarter. Procyon Advisors LLC raised its holdings in shares of Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after acquiring an additional 63 shares in the last quarter. Finally, Coppell Advisory Solutions LLC raised its holdings in Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after purchasing an additional 64 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,862 shares of company stock valued at $312,254. Corporate insiders own 0.16% of the company's stock.

Zoetis Stock Performance

NYSE ZTS traded up $1.96 on Tuesday, reaching $155.53. 2,065,141 shares of the company's stock traded hands, compared to its average volume of 2,487,707. The firm has a market cap of $69.39 billion, a price-to-earnings ratio of 28.43, a P/E/G ratio of 2.78 and a beta of 0.92. The stock has a 50 day moving average price of $158.81 and a 200-day moving average price of $167.98. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.29%. Zoetis's payout ratio is 36.56%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus lowered their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Piper Sandler raised their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $214.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.